HOME >> BIOLOGY >> NEWS
Interim data suggest major response with Aranesp(R) in anemic patients with MDS

THOUSAND OAKS, Calif., Jul 06, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). The data were presented at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC) in Geneva. (Abstract #02-007)

"The majority of MDS patients develop clinically significant anemia during the course of their disease, which often leads to fatigue and increased red blood cell transfusions," said Janice Gabrilove, M.D., professor of medicine, hematology and medical oncology at Mount Sinai School of Medicine, New York and the study's lead investigator. "In this study, low risk MDS patients receiving Aranesp every three weeks, who had no prior erythropoietic therapy, exhibited an overall response of 77 percent, increased hemoglobin levels and improvements in patient reported fatigue."

Results of an interim analysis were presented from the first 100 patients of an approximately 200 patient, Phase 2, single arm study of low risk MDS patients (those with a low risk of progressing to acute myeloid leukemia) with anemia and treated with Aranesp 500 mcg administered every three weeks. Of the 100 patients evaluated, 63 percent had no prior erythropoietic agent use. The primary endpoint of the study was the proportion of patients achieving an erythroid response (defined in accordance with the International Working Group Response Criteria) during the 13-week test period. Secondary endpoints included changes in hemoglobin level from baseline, incidence of transfusions and impact on patient reported fatigue.

Results were presented for all 100 patients for incidence of transfusion and patient reported fatigue and 90 patients were evaluated for erythroid respon
'"/>

Contact: Trish Hawkins
plange@amgen.com
805-447-5631
Porter Novelli
6-Jul-2005


Page: 1 2 3 4

Related biology news :

1. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
2. Interim Aranesp data suggest major response in anemic patients with MDS
3. Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP
4. Features of replication suggest viruses have common themes, vulnerabilities
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
7. Experiment suggests limitations to carbon dioxide tree banking
8. Immunity in social amoeba suggests ancient beginnings
9. New model for autism suggests women carry the disorder and explains age as a risk factor
10. Pediatric ritalin use may affect developing brain, new study suggests
11. Oldest DNA ever recovered suggests earth was warmer than previously believed

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):
(Date:2/28/2017)...  Phosphorus, a computational genomics and clinical genetic ... Phosphorus Scientific Advisory Board, an established group of ... company on the development of new products and ... http://phosphorus.com/about-us/ to learn more about the ... some of the top leaders in the field ...
(Date:2/28/2017)... , Feb. 28, 2017 WuXi AppTec, ... open-access capability and technology platform company, today announced ... Shanghai once again passed ... observations. The inspectors from FDA thoroughly ... focusing on scientific data integrity, operation infrastructure, equipment, ...
(Date:2/28/2017)... ... 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the ... (Feng) Luo as the new Vice President of Global Clinical Development. With more ... Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, and Dr. ...
(Date:2/28/2017)... and PHILADELPHIA , Feb. 28, 2017 ... held biopharmaceutical company focusing on debilitating diseases including rare ... announced that the company joins with the National Organization ... advocacy and support around the world in commemorating Rare ... unique challenges and needs of the millions of patients ...
Breaking Biology Technology:
Cached News: